Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Nxera previously announced the initiation of the Phase 3 registrational program of NBI-'568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-'568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS). The key secondary endpoint is improvement in the Clinical Global Impression of Severity (CGI-S) scale.
–END–
About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation.
Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life
MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
What Adyen's tariff troubles portend for payments companies
Tariffs and the subsequent global trade war are hurting Adyen's financial outlook, causing the company to seek ways to deemphasize the U.S. "The tariffs are impacting some of our Asia Pacific merchants," Adyen CEO Ingo Uytdehaage said during Adyen's earnings the first half of 2025, Adyen reported net revenue of $1.27 billion, lower than the $1.3 billion forecast by LSEG analysts. First half earnings before interest, taxes and amortization were $635 million, lower than the $643 million estimated by analysts. Adyen also said its previously forecast "slight net revenue growth" is "unlikely" due to an increasingly uncertain macroeconomics. Adyen did not return a request for comment. Beyond the impact of tariffs, Adyen reported strong results, such as wallet share gains among existing merchants and improvements in adding new customers. But "the downward revision in full year net revenue growth guidance and commentary suggesting a persistent macro headwind in the second half will likely overshadow the positive data points," KeyBanc Capital Markets said in an analyst note on Adyen. "We walk away incrementally cautious on the balance of the year." Less focus on the U.S. Adyen, which is headquartered in Amsterdam, also has operations in the U.S. The company has accumulated a portfolio of payment and financial services products in competition with Stripe, Block, PayPal and other companies that sell payment technology to small businesses globally. Uytdehaage told analysts that it would attempt to route more transactions from China to non-U.S. consumers to reduce economic pressure from the trade war. "That's how we look at things we can't control," Uytdehaage said of viewing the tariffs as an "opportunity." "We can help those merchants move into new markets." While payment firms are looking at how tariffs and tighter immigration policy impact inflation and payment volume, there's one particular change that is heavily impacting China, and thus could hit Asian payment volume particularly hard. Read more about tariffs. Tariffs and Banking: Key Insights and Analysis | American Banker In Adyen's case the tariff impacts partly include the suspension of the de minimus rule. Tariffs for goods under $800 traditionally were waived under the rule. Large firms that sell Chinese goods, such as Temu and Shein, are subject to the de minimus rule's discontinuation given their large sales volumes of lower-cost items to the U.S. via e-commerce. Losing the $800 waiver exposes small purchases to the same uncertain tariffs as larger purchases. Adyen did not disclose its exposure to Shein or Temu, but its revenue includes transaction fees from online retailers, and Adyen attributed its tariff pressure to slower growth from APAC merchants with U.S. e-commerce customers. Downstream pressure While payment companies have mostly projected stronger than expected earnings for 2025, analysts said the recent imposition of new tariffs threaten those outlooks. "While we expect fundamentals in the second quarter to hold up, estimates for many payments companies anticipate a stronger second half relative to the first half driven by timing of growth initiatives or favorable comps," KBW said in a research report on the broader global payments industry. "The key question is whether confidence in the achievability of these growth targets remains intact as the impacts from tariffs in the second half come back into focus." Areas to watch include travel, discretionary online retail given the de minimis tax exemption to China going away, and restaurant spending, according to KBW. "But a weaker dollar should be an incremental tailwind for most of the companies in our coverage," KBW said. The notion that tariffs won't impact the payments industry is wishful thinking or denial, Eric Grover, principal at Intrepid Ventures, told American Banker, noting that tariffs are a tax on imports and are increasing the price of goods for consumers and producers. "They will, therefore, very directly reduce commerce and consequently payments," Grover said. "Cross-border e-commerce is likely to be most immediately and acutely impacted, which is why Adyen in particular is feeling the pain. But the rest of the payments industry isn't immune. Payment networks and processors will suffer, some more than others depending on their mix of business." Adyen has had more exposure outside the U.S., where the impact of tariffs is more likely to be felt, particularly in Asia, Aaron McPherson, principal at AFM Consulting, told American Banker. Another important factor is the delay in tariffs, which has muted their impact thus far, McPherson businesses have absorbed the impact of tariffs, but may soon have to pass on the cost of tariffs to consumers because the businesses can no longer afford the extra expense. Inflation in the U.S. has started to increase along with signs of a weakening labor market. Given these factors, Adyen's relatively weak earnings report may be a harbinger of problems to come, according to McPherson. "We'll need to see more corporate reporting to gauge the full effect of the tariffs, but given that the majority of them only went into effect this week, they would not have shown up in last quarter's numbers anyway," he said. Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Taiwan Semiconductor Manufacturing Company Limited (TSM) Is Worried About High Construction Costs Of US Plants, Says Jim Cramer
We recently published . Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) is one of the stocks Jim Cramer recently discussed. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) isn't a frequent feature of Cramer's morning show despite the fact that the firm is the world's largest contract chip manufacturer. His previous remarks about the company have pointed out that most of its revenue gains are due to orders from NVIDIA. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) is playing a key role in bringing chip manufacturing to the US through its multi-billion-dollar facilities in Arizona. However, the firm has faced some troubles, such as rising costs and cultural differences. Here is what Cramer said about Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM): 'By the way, Taiwan Semi is saying it costs a huge amount of money to build here versus Arizona.' the-main-processor-3334336_1280 Previously, the CNBC TV host discussed Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM)'s earnings and financial performance: 'Yeah look, Taiwan Semi reports overnight. It's an unbelievably good number but understand it's really unbelievably good number because of high performance computing. In other words, it's a good number because of NVIDIA. While we acknowledge the potential of TSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Bloomberg
20 minutes ago
- Bloomberg
Difficult to See Bessent Size Rate Cut: Kathy Jones
US Treasury Secretary Scott Bessent made his most explicit call yet for the Federal Reserve to execute a cycle of interest-rate cuts, suggesting the central bank's benchmark ought to be at least 1.5 percentage points lower than it is now. However, Schwab Center for Financial Research Chief Fixed Income Strategist Kathy Jones says it is difficult to make the case for a big cut unless they are looking for the economy to fall off a cliff. She speaks with Vonnie Quinn on 'Bloomberg Markets.' (Source: Bloomberg)
